Edgewood Oncology Announces First Patients Dosed in Phase IIa Study of BTX-A51 in Genetically-Defined Breast Cancer

Edgewood Oncology announced that the first two patients with metastatic breast cancer were treated with BTX-A51, a multi-specific kinase inhibitor of casein kinase 1 alpha and cyclin-dependent kinases 7 and 9, that synergistically targets master regulators of cancer.